Asthma

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

Researchers link vaccination and reduced asthma symptoms; providers warn against overburdening and security risks; insurers’ practices lead to questionable diagnoses

Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.

Black children with asthma are disproportionately exposed to asthma triggers and access barriers, according to one study.

Posters presented at the American Thoracic Society (ATS) 2024 International Conference examined factors of the pandemic that may have influenced the clinical presentation and diagnosis of respiratory symptoms, as well as health care resource utilization for serious asthma outcomes.

Underlying mood and sleep disorders may negatively affect asthma control, researchers find.

Asking patients about their diet is important when evaluating for adult-onset asthma, allergic disease, and aspirin-exacerbated respiratory disease (AERD).

The introduction of the Global Initiative for Asthma 2019 guidelines significantly improved treatment of children with mild asthma, according to one study.

Significant improvements were seen in ventilation heterogeneity in patients with severe asthma after 12 months of bronchial thermoplasty.

Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.

COVID-19 likely does not increase the risk of asthma development in pediatric patients, research suggests.

The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study.

Public health policies should address risk factors among individuals who are most at risk of asthma, researchers suggest.

President Joe Biden and Senator Bernie Sanders continue their push to cut the cost of asthma inhalers and prescription drugs in the US.

Patients with acute asthma exacerbations who do not suppress eosinophils after a course of oral corticosteroids (OCS) may have slower clinical recovery, according to one study.

The researchers found that popularity of videos did not necessarily correlate with the quality of information provided in the video.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Areas with high proportions of Black and Latinx residents face high rates of asthma-related emergency department visits, according to one study.